Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multi-centre, Randomized, Partially Placebo-controlled, Double-blind Study to Investigate the Safety and Efficacy of Sequential Therapy With Daplusiran/Tomligisiran Followed by Bepirovirsen in Participants With Chronic Hepatitis B Virus on Background Nucleos(t)Ide Analogue Therapy (B-United)

NCT06537414 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06537414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06537414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multi-centre, Randomized, Partially Placebo-controlled, Double-blind Study to Investigate the Safety and Efficacy of Sequential Therapy With Daplusiran/Tomligisiran Followed by Bepirovirsen in Participants With Chronic Hepatitis B Virus on Background Nucleos(t)Ide Analogue Therapy (B-United)
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 11, 2024
Completion date
May 17, 2030
Enrollment
283 (actual)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b virus infection, hepatitis b